

**Amendments to the Claims:**

Please amend claims 1, 3, 5, 7-9, 12 and 15-18.


Please cancel claims 19 and 20.

Please add new claims 21-24.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of the general formula (I):



wherein R' represents an anti-epileptic drug (AED), anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety;

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

2. (original) The compound according to claim 1, wherein R' is an anti-epileptic drug moiety.
3. (currently amended) The compound according to claim 2, wherein said anti-epileptic drug is selected from the group consisting of phenytoin ~~or~~ and other hydantoin; phenobarbital ~~or~~ and other barbiturates, primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate, gabapentin, lamotrigine, vigabatrin and adrenocorticotrophic hormone (ACTH).
4. (original) The compound according to claim 1, wherein R' represents a moiety of  $\gamma$ -aminobutyric acid and/or kynurenic acid.

5. (currently amended) A composition comprising a physical mixture of:


(a) at least one substance selected from the group consisting of pyridoxal, pyridoxamine and pyridoxine, their pharmaceutically acceptable functional derivatives and salts thereof; and

(b) at least one anti-epileptic drug AED, anticonvulsive drug, neuroprotective drug or nootrope compound.

6. (original) The composition according to claim 5, wherein component (b) is an anti-epileptic drug.

7. (currently amended) The composition according to claim 6, wherein said anti-epileptic drug is selected from the group consisting of phenytoin ~~or~~ and other hydantoins; phenobarbital ~~or~~ and other barbiturates, primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate, gabapentin, lamotrigine, vigabatrin and adrenocorticotrophic hormone (ACTH).

8. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of the general formula (I)




---

and a pharmaceutically acceptable carrier or excipient, wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.


9. (currently amended) The pharmaceutical composition according to claim 8, wherein the compound of the general formula (I) having R' in an amount which is no greater than the maximal safe amount for a single administration of the attached anti-epileptic drug (AED),

anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope component.

10. (original) A pharmaceutical composition comprising therapeutically effective amounts of components (a) and (b) as defined above in claim 5, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

11. (original) The pharmaceutical composition according to claim 10, wherein components (a) and (b) are present in dosages no greater than their respective maximal safe dosages for a single administration.

12. (currently amended) A method of treatment of a neurological disease or disorder comprising administering to an individual in need thereof a therapeutically effective amount of a compound of the general formula (I):



wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and


R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

13. (original) A method of treatment of a neurological disease or disorder comprising administering to an individual in need thereof a therapeutically effective amount of a composition in accordance with claim 5.

14. (original) A method of treatment of a neurological disease or disorder comprising co-administering to an individual in need thereof a therapeutically effective amounts of components (a) and (b) as defined in claim 5, in separate compositions.

15. (currently amended) The method ~~according to any one of claims 12 to 14~~, wherein said neurological disease or disorder is epilepsy.

16. (currently amended) A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of ~~AEDs~~ anti-epileptic drugs comprising the step of administering to a subject a therapeutically effective amount of a compound of the general formula (I):



wherein R' represents an anti-epileptic drug, anticonvulsive drug, neuroprotective drug, neurotransmitter or nootrope moiety; and

R is selected from the group consisting of -CH<sub>2</sub>OH, -CHO and -CH<sub>2</sub>NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

17. (currently amended) A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of ~~AEDs~~ anti-epileptic drugs comprising the step of administering to a subject: (a) at least one substance selected from the group consisting of pyridoxal, pyridoxamine and pyridoxine, their pharmaceutically acceptable functional derivatives and salts thereof, in an amount which is equivalent to from about 2 to about 500 times the recommended daily dietary allowance of pyridoxine; in combination with (b) at least one ~~AED~~ anti-epileptic drug, anticonvulsive, neuroprotective drug or nootrope compound.

18. (currently amended) The method according to ~~any one of claims 12 to 17~~, wherein said compound ~~or composition~~ is orally administered.

19. (canceled).

20. (canceled).

21. (new) The method of claim 13, wherein said neurological disease or disorder is epilepsy.
22. (new) The method according to claim 13, wherein said composition is orally administered.
23. (new) The method of claim 14, wherein said neurological disease or disorder is epilepsy.
24. (new) The method of claim 14, wherein said compositions are orally administered.